Pharmaceutical giant Mylan has initiated a voluntary recall affecting 13 lots of EpiPen and EpiPen Jr. devices across the nation, citing a possible defect with the product. The EpiPen is crucial for individuals facing severe allergic reactions, which is why the company is taking this precautionary measure.
As detailed on Mylan’s official website, the likelihood of encountering the defect is minimal. However, the company is acting “out of an abundance of caution” to ensure that any potentially defective devices are removed from circulation. This recall follows two reports from outside the U.S. regarding devices that failed to activate due to a flaw in a supplier’s component. Both incidents were linked to a single lot that had already been recalled, prompting Mylan to expand the recall to include additional lots for safety.
The defect, if present, could hinder the EpiPen from activating properly, either requiring excessive force or failing entirely, which could delay critical treatment during a severe allergic episode. The affected lots of EpiPen and EpiPen Jr. were distributed between December 17, 2015, and July 1, 2016. A chart detailing the specific lot numbers and expiration dates is available on Mylan’s website.
This isn’t the first time Mylan has been in the spotlight regarding EpiPen pricing, as the device’s price increase led to significant public backlash last summer. After considerable criticism, the company reduced the price from a staggering $600 to $300, despite the production cost being around $30. While the price remains high, it is reassuring to see Mylan prioritize user safety by addressing this potential issue.
Consumers are advised to check their EpiPens, including those kept at schools, to ensure they are not part of the recalled lots. If they are, Mylan’s website provides instructions for obtaining a replacement. The company recommends that users retain their current pens until a new one is available.
For additional information on pregnancy and home insemination, you can visit this excellent resource here. To explore more about this topic, you might find our other post on intracervical insemination interesting. For those seeking to enhance their fertility, check out Make a Mom for valuable supplements.
Summary
Mylan has voluntarily recalled 13 lots of EpiPen and EpiPen Jr. devices due to a potential defect that could impede activation. While the risk is low, the company aims to ensure user safety by proactively addressing the issue. Affected consumers should check their pens and follow the recall instructions provided by Mylan.